Editor's note: HBW Insight’s ongoing feature provides information on decisions during August-October by the US Food and Drug Administration on new drug applications, including ANDAs, for nonprescription drugs and on supplemental NDAs about label and package changes for approved OTC products.
The past three months offered relatively little in the way of additional OTC drug products approved for sales in the...







